Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ · Healthcare · Biotechnology
Profile
Vertex Pharmaceuticals Incorporated
- Exchange
- NASDAQ
- Ticker
- VRTX
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Key facts
Vertex Pharmaceuticals Incorporated: key facts
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Vertex Pharmaceuticals Incorporated reported revenue of $12.1B and net income of $4.0B.
- Revenue grew 12.4% a year over the last 4 fiscal years.
- Free cash flow was positive in 4 of the last 5 fiscal years.
- Net income was positive in 4 of the last 5 fiscal years.
- Over the last twelve months, revenue was $12.6B and net income was $4.4B.
MonkScore
Vertex Pharmaceuticals Incorporated's MonkScore
MonkScore
MonkScore range: 70–80
as of October 2026
Sector rank: 167 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth50–60
- Profitability80–90
- Quality50–60
- Market Conviction60–70
- Safety60–70
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Vertex Pharmaceuticals Incorporated's annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $12.6B | $12.1B | $11.0B | $9.9B | $8.9B | $7.6B |
| Gross profit | $10.9B | $10.3B | $9.5B | $8.6B | $7.9B | $6.7B |
| Operating income | $4.9B | $4.8B | -$232.9M | $3.8B | $4.3B | $2.8B |
| Net income | $4.4B | $4.0B | -$535.6M | $3.6B | $3.3B | $2.3B |
| Operating cash flow | $4.3B | $3.6B | -$492.6M | $3.5B | $4.1B | $2.6B |
| Capital expenditure | -$496.8M | -$437.6M | -$297.7M | -$258.4M | -$204.7M | -$235.0M |
| Free cash flow | $3.8B | $3.2B | -$790.3M | $3.3B | $3.9B | $2.4B |
| Total debt | $2.0B | $3.9B | $1.7B | $808.4M | $899.7M | $967.4M |
| Cash | $6.1B | $5.1B | $4.6B | $10.4B | $10.5B | $6.8B |
Revenue growth a year
- 1-year
- 9.6%
- 3-year
- 10.6%
- 4-year
- 12.4%
Compound growth between fiscal years.
Peers
Similar companies
- OmniAb, Inc.NASDAQ:OABIMonkScore range: 70–80
- Maravai LifeSciences Holdings, Inc.NASDAQ:MRVIMonkScore range: 70–80
- Puma Biotechnology, Inc.NASDAQ:PBYIMonkScore range: 70–80
- Nurix Therapeutics, Inc.NASDAQ:NRIXMonkScore range: 80–90
- Kymera Therapeutics, Inc.NASDAQ:KYMRMonkScore range: 80–90
- TG Therapeutics, Inc.NASDAQ:TGTXMonkScore range: 80–90
- Tarsus Pharmaceuticals, Inc.NASDAQ:TARSMonkScore range: 80–90
- Ardelyx, Inc.NASDAQ:ARDXMonkScore range: 80–90
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.